Samsung Biologics Co Ltd (207940) Fair Value & Analysis
Healthcare · KR · Market cap 64.8T KRW (≈ $45.4B) · ISIN KR7207940008
What is Samsung Biologics Co Ltd really worth?
A strong business, but trading 37% above our fair value of 1,055,793 KRW.
Strengths
Risks
Fair value as of: Sep 1, 2026
From 24 valuation models · updated 4 days ago
Share price +1.7% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A high-quality business (quality 82/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (1,410,628 KRW). The favourable scenario is already priced in.
- A fairly wide model range (553,298 KRW to 1,410,628 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 1, 2026.
How to read this chart
60‑month range 1,045,524 KRW – 1,965,000 KRW · fair‑value band 553,298 KRW – 1,410,628 KRW · the 1,447,000 KRW price screens above the 1,055,793 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 1, 2026.
Analysis
Samsung Biologics Co Ltd (207940) currently trades at 1,447,000 KRW, while our model-based Fair Value estimate is 1,055,793 KRW, implying the stock looks roughly 37.1% overvalued today. The Quality Score stands at 82/100 (high quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of 1,790,868 KRW per share, and 2 of the 24 models we run sit above the 1,447,000 KRW price. Bear case: the Asset-Based group reads lowest at 107,845 KRW, and 22 of the 24 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Samsung Biologics Co Ltd generated revenue of 4.8T KRW at a net margin of 39.0%. Revenue grew 25.8% year over year. It earns a return on equity of 18.3%. Net debt stands at 770B KRW. Fundamentals as of Sep 1, 2026
Our scenario range runs from 553,298 KRW (bear case) to 1,410,628 KRW (bull case); at 1,447,000 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 45% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −59% fair-value upside, at −27%, 207940 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: Growth Earnings (1,790,868 KRW) versus Asset-Based (107,845 KRW). Highest evidence: EPV (74).
Notify me when 207940 reaches fair value
Put 207940 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 1, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 77 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally.
Full company description
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Samsung Biologics Co Ltd reported revenue of 4.6T KRW in FY2025 versus 1.6T KRW in FY2021, a compound +30.6%/yr. Reported net income was 1.8T KRW in FY2025, compounding +45.9%/yr from FY2021.
207940 screens 37% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Sep 1, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| CSL Limited CSL | A$174.50 | A$141.68 | −19% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | −69% |
| BioNTech SE BNTX | $111.40 | $45.66 | −59% |
| Incyte Corporation INCY | $123.22 | $115.79 | −6% |
Compare Samsung Biologics Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Samsung Biologics Co Ltd (207940) overvalued or undervalued?
What is the fair value of 207940?
What is the quality score of 207940?
What is the revenue of Samsung Biologics Co Ltd (207940)?
What is the net profit margin of 207940?
Watch Samsung Biologics Co Ltd in the live analysis
One click puts Samsung Biologics Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.